A Study to Investigate the Preventive Effect of AG-1749 Against the Recurrence of Gastric and Duodenal Ulcers During Long-Term Treatment With Nonsteroid Anti-Inflammatory Drug.

Trial Profile

A Study to Investigate the Preventive Effect of AG-1749 Against the Recurrence of Gastric and Duodenal Ulcers During Long-Term Treatment With Nonsteroid Anti-Inflammatory Drug.

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Jun 2016

At a glance

  • Drugs Lansoprazole (Primary) ; Gefarnate
  • Indications NSAID-induced ulcer
  • Focus Therapeutic Use
  • Sponsors Takeda Pharma
  • Most Recent Events

    • 08 Jul 2009 Actual number of patients (366) added as reported by ClinicalTrials.gov.
    • 08 Jul 2009 Actual end date (May 2009) added as reported by ClinicalTrials.gov.
    • 08 Jul 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top